CHRETO - A paradigm shift in mAb purification

CHRETO is revolutionizing mAb purification through its innovative biotechnology solutions. With a focus on radically improving process efficiency in downstream processing of large biomolecules, CHRETO's technology aims to increase yields in existing production, particularly in IVIG, and expedite the development and testing of monoclonal antibody (mAb) candidates. CHRETO's protein purification technology represents a significant advancement in bio-manufacturing.

Founded in 2010 as a spin-out of Novozymes, CHRETO is dedicated to commercializing a novel protein purification technology. The company's purification process consists of three key steps: catch, clean, and collect. This innovative approach promises process improvements and significant cost reductions in manufacturing materials for clinical trials.

CHRETO is located at LejrVej 17, Vaerloese, DK DK-3500, DK. The team at CHRETO is committed to advancing bio-manufacturing through cutting-edge technology. We invite the manager of CHRETO to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.